Published in PLoS One on November 14, 2013
Study of Ramucirumab in Ovarian Cancer | NCT00721162
A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma | NCT00515697
A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer | NCT00862784
Genetic alteration profiling of patients with resected squamous cell lung carcinomas. Oncotarget (2016) 0.89
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer (2016) 0.82
Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer. Int J Oncol (2015) 0.76
Variability in Platelet-Derived Growth Factor Receptor Alpha Antibody Specificity May Impact Clinical Utility of Immunohistochemistry Assays. J Histochem Cytochem (2016) 0.75
Fibroblast Growth Factor Receptor 1 (FGFR1), Partly Related to Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and Microvessel Density, is an Independent Prognostic Factor for Non-Small Cell Lung Cancer. Med Sci Monit (2017) 0.75
Expression of VEGFR2 and NRP-1 in non-small cell lung cancer and their clinical significance. Chin J Cancer Res (2014) 0.75
Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer. BMC Urol (2017) 0.75
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Angiogenesis as a therapeutic target. Nature (2005) 11.89
Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med (2002) 8.04
The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer (2004) 6.32
Vascular endothelial growth factor and angiogenesis. Pharmacol Rev (2004) 5.41
Antibody validation. Biotechniques (2010) 4.42
Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res (1999) 4.20
VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature (2002) 4.10
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71
The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res (1996) 2.57
VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem (2002) 2.53
Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst (1995) 2.44
Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J (2000) 1.78
Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol (2011) 1.78
Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology (1999) 1.71
Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol (2008) 1.61
Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer (2000) 1.58
Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis (2007) 1.56
The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med (Berl) (2002) 1.54
Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res (2010) 1.48
Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ (2001) 1.47
Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol (2005) 1.44
Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res (2007) 1.41
Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol (2000) 1.41
Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol (1993) 1.37
VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. Exp Cell Res (2007) 1.32
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther (2007) 1.32
Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer (2000) 1.30
Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest (2007) 1.26
High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol (2008) 1.26
Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood (2004) 1.26
Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A (2011) 1.26
Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res (2000) 1.25
The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer (2001) 1.16
Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol (2007) 1.15
Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int J Cancer (2009) 1.13
Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One (2012) 1.12
Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer (2006) 1.12
VEGFR2 translocates to the nucleus to regulate its own transcription. PLoS One (2011) 1.12
The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study. Histopathology (2003) 1.09
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2007) 1.07
Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol (2012) 1.06
Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett (1997) 1.06
Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat (2003) 1.04
Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res (2000) 1.03
Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist (2009) 1.02
Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur J Cancer (2006) 0.98
Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer (2005) 0.98
Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets (2002) 0.98
Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. Oncologist (2010) 0.96
Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am J Clin Pathol (2001) 0.94
Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors. Am J Surg Pathol (2012) 0.94
High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clin Cancer Res (2009) 0.90
Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization. Biotechniques (2012) 0.89
Expression of VEGFR-2 on HaCaT cells is regulated by VEGF and plays an active role in mediating VEGF induced effects. Biochem Biophys Res Commun (2006) 0.89
Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells. Lab Invest (2010) 0.88
VEGFR-2 expression in human melanoma: revised assessment. Int J Cancer (2011) 0.83
Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma. Respiration (2000) 0.81
Tumorigenesis and the angiogenic switch. Nat Rev Cancer (2003) 11.95
Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome. Nat Genet (2004) 8.24
Evolution of protein kinase signaling from yeast to man. Trends Biochem Sci (2002) 5.28
Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature (2010) 4.85
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell (2006) 4.55
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol (2010) 3.15
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer (2010) 2.74
The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem (2004) 2.46
Microvascular patterning is controlled by fine-tuning the Akt signal. Proc Natl Acad Sci U S A (2004) 2.39
Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics (2014) 2.37
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res (2007) 2.15
MRI detection of transcriptional regulation of gene expression in transgenic mice. Nat Med (2007) 2.09
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 2.03
Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med (2012) 2.00
Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res (2008) 1.99
Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat (2009) 1.83
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res (2007) 1.82
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res (2011) 1.71
Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1. Cancer Biol Ther (2004) 1.62
Blood markers for vasculogenesis increase with tumor progression in patients with breast carcinoma. Cancer Biol Ther (2003) 1.60
Identification and characterization of a major liver lysophosphatidylcholine acyltransferase. J Biol Chem (2008) 1.60
Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res (2013) 1.59
Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem (2007) 1.58
Circulating human hepcidin-25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration. Clin Chem (2012) 1.57
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res (2010) 1.56
Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro. Blood (2006) 1.53
A single nucleotide polymorphism in MGEA5 encoding O-GlcNAc-selective N-acetyl-beta-D glucosaminidase is associated with type 2 diabetes in Mexican Americans. Diabetes (2005) 1.52
Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A (2005) 1.51
AGPAT6 is a novel microsomal glycerol-3-phosphate acyltransferase. J Biol Chem (2008) 1.50
RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev (2003) 1.48
Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst (2012) 1.47
Obligatory participation of macrophages in an angiopoietin 2-mediated cell death switch. Development (2007) 1.47
Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal (2009) 1.43
Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease. Endocr Metab Immune Disord Drug Targets (2008) 1.39
Strategic use of immunoprecipitation and LC/MS/MS for trace-level protein quantification: myosin light chain 1, a biomarker of cardiac necrosis. Anal Chem (2007) 1.36
Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res (2002) 1.36
Clinical field study of the safety and efficacy of spinosad chewable tablets for controlling fleas on dogs. Vet Ther (2008) 1.36
Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol (2009) 1.35
Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression. Cancer Res (2007) 1.32
Decreased vascular lesion formation in mice with inducible endothelial-specific expression of protein kinase Akt. J Clin Invest (2006) 1.31
Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. Arterioscler Thromb Vasc Biol (2009) 1.29
Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res (2008) 1.29
Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem Biophys Res Commun (2008) 1.26
Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom (2006) 1.22
Serum markers of bone turnover are increased at six and 18 months after Roux-en-Y bariatric surgery: correlation with the reduction in leptin. J Clin Endocrinol Metab (2009) 1.20
Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. J Proteome Res (2010) 1.20
Glycerolipid acyltransferases in triglyceride metabolism and energy homeostasis-potential as drug targets. Endocr Metab Immune Disord Drug Targets (2012) 1.19
Vitamin D and hyperparathyroidism in obesity. J Clin Endocrinol Metab (2011) 1.17
Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res (2008) 1.16
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res (2013) 1.16
Mastication of almonds: effects of lipid bioaccessibility, appetite, and hormone response. Am J Clin Nutr (2009) 1.08
Analysis of glutamine, glutamate, pyroglutamate, and GABA in cerebrospinal fluid using ion pairing HPLC with positive electrospray LC/MS/MS. J Neurosci Methods (2008) 1.07
Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice. J Lipid Res (2007) 1.05
Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol (2010) 1.03
An apolipoprotein A-I mimetic dose-dependently increases the formation of prebeta1 HDL in human plasma. J Lipid Res (2007) 1.02
Analytical validation and biological evaluation of a high molecular-weight adiponectin ELISA. Clin Chem (2007) 1.01
Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases. Gynecol Oncol (2007) 0.99
A dual-monoclonal sandwich ELISA specific for hepcidin-25. Clin Chem (2010) 0.99
Akt promotes endocardial-mesenchyme transition. J Angiogenes Res (2009) 0.99
Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina. Am J Physiol Heart Circ Physiol (2009) 0.97
Primary mixed lymphoepithelioma-like carcinoma and intra-hepatic cholangiocarcinoma: a case report and review of literature. Int J Clin Exp Pathol (2010) 0.96
Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature. Hum Pathol (2008) 0.96
Simultaneous profiling of multiple neurochemical pathways from a single cerebrospinal fluid sample using GC/MS/MS with electron capture detection. J Mass Spectrom (2008) 0.96
Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis (2010) 0.95
T-large granular lymphocyte leukemia: current molecular concepts. Hematology (2006) 0.94
Validating regulatory-compliant wide dynamic range bioanalytical assays using chip-based nanoelectrospray tandem mass spectrometry. Rapid Commun Mass Spectrom (2005) 0.94
Alloxan is an inhibitor of O-GlcNAc-selective N-acetyl-beta-D-glucosaminidase. Biochem Biophys Res Commun (2006) 0.94
Correlation between Mcl-1 and pAKT protein expression in colorectal cancer. Int J Clin Exp Pathol (2010) 0.94
Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J Lipid Res (2009) 0.93
Oxidative stress improves coronary endothelial function through activation of the pro-survival kinase AMPK. Aging (Albany NY) (2013) 0.93
Ischemic time impacts biological integrity of phospho-proteins in PI3K/Akt, Erk/MAPK, and p38 MAPK signaling networks. Anticancer Res (2011) 0.92
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study. Invest New Drugs (2009) 0.91
The acyl coenzymeA:monoacylglycerol acyltransferase 3 (MGAT3) gene is a pseudogene in mice but encodes a functional enzyme in rats. Lipids (2011) 0.91
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol (2014) 0.90
An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods (2007) 0.90
Optimization of analytical and pre-analytical variables associated with an ex vivo cytokine secretion assay. J Pharm Biomed Anal (2006) 0.90
Insulin-like growth factor 1 receptor activates c-SRC and modifies transformation and motility of colon cancer in vitro. Anticancer Res (2003) 0.90
Administration of a PPARalpha agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio. J Lipid Res (2005) 0.90
Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates. J Clin Lab Anal (2013) 0.90
Quantification of gemcitabine incorporation into human DNA by LC/MS/MS as a surrogate measure for target engagement. Anal Chem (2010) 0.89
The microsomal cardiolipin remodeling enzyme acyl-CoA lysocardiolipin acyltransferase is an acyltransferase of multiple anionic lysophospholipids. J Lipid Res (2008) 0.88
Altered lipid raft composition and defective cell death signal transduction in glycosylphosphatidylinositol anchor-deficient PIG-A mutant cells. Br J Haematol (2008) 0.87
Hyperinsulinemia fails to augment ET-1 action in the skeletal muscle vascular bed in vivo in humans. Am J Physiol Endocrinol Metab (2008) 0.87
Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels. Arterioscler Thromb Vasc Biol (2012) 0.86
Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab. J Alzheimers Dis (2013) 0.86
Definitive N-terminal protein sequence and further characterization of the novel apolipoprotein A5 in human serum. Clin Chem (2006) 0.85
Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET). Histopathology (2014) 0.85
A novel splicing variant of proprotein convertase subtilisin/kexin type 9. DNA Cell Biol (2008) 0.85
RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis. Cancer Res (2012) 0.85
Quantification of serine enantiomers in rat brain microdialysate using Marfey's reagent and LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.85